| Identification | Back Directory | [Name]
Trastuzumab | [CAS]
180288-69-1 | [Synonyms]
Herceptin
RhuMab HER2
Trastuzumab Beta
TRASTUZUMAB 95 % +
TRASTUZUMAB 98 % +
Trastuzumab USP/EP/BP
TrastuzuMab(Herceptin)
Trastuzumab (anti-HER2)
Trastuzumab,Stock solution
Trastuzumab - 20mg/ml in PBS
Anti HER2, Ig gamma-1 chain C region
Recombinant humanized anti-HER2 antibody
IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer | [Molecular Formula]
C10H14N6O5 | [MDL Number]
MFCD03702625 | [MOL File]
180288-69-1.mol | [Molecular Weight]
298.255 |
| Hazard Information | Back Directory | [Uses]
Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer. | [Definition]
Herceptin (generic name: trastuzumab) is not a chemo drug, it is a targeted therapy anticancer drug.
Herceptin contains one active ingredient, trastuzumab, and is given as an intravenous (IV) infusion slowly into a vein. Herceptin Hylecta contains two active ingredients, trastuzumab and hyaluronidase-oysk, and is given as a subcutaneous injection, which is an injection that goes under the skin.
| [Indications]
The introduction of herceptin (Trastuzumab) into clinical
practice for the treatment of breast cancer marks a
major advance in the use of monoclonal antibody cancer
therapy. Herceptin is a humanized antibody directed
against the HER-2 antigen that is overexpressed
on the tumor cell surface in approximately 25% of
breast cancer patients. HER-2/neu/erbB2 overexpression
marks an aggressive estrogen receptor–negative
form of breast cancer. Therefore, a therapeutic agent
selective for this target is particularly valuable.
Herceptin is administered by intravenous infusion and
in conjunction with paclitaxel can extend survival in
patients with HER-2/neu/erbB2 overexpressing metastatic
breast cancer.Herceptin use is associated with infusion-
related hypotension, flushing and bronchoconstriction,
and skin rash but no bone marrow toxicity.
Herceptin appears to sensitize patients to cardiotoxicity,
an important concern in patients also receiving
doxorubicin. | [Mechanism of action]
Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to an extracellular domain of this receptor and inhibits HER2 homodimerization, thereby preventing HER2-mediated signaling. It is also thought to facilitate antibody-dependent cellular cytotoxicity, leading to the death of cells that express HER2. Its mechanism differs slightly from that of the newer agent pertuzumab; the latter inhibits hetero-dimerization of HER2 with HER3, a related growth factor receptor. Trastuzumab has been shown to bind three distinct regions of domain IV of the HER2 extracellular domain through electrostatic and hydrophobic bindings[1].
| [References]
[1] Hamid Maadi. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.” Cancers (2021).
|
|
|